PR
Prostatype Genomics AB (publ)
PROGEN.ST · STO
0.16 kr -6.47% (-0.01 kr)
1M +62.24%
Market Cap 5.61M kr
P/E Ratio -
Div. Yield -
ROE 185.25%
Bulios Fair Price
0.23 kr
44.7% upside
Trenutna cena
0.16 kr
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica PROGEN.ST trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 9.44x
P/B 0.21x
P/E N/A
Growth
6 /100
Declining Rev. growth 4.55%
Book val. growth 0.48%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 6,332.66%
Net margin 7,492.09%
FCF margin 4,050.34%
Quality
0 /100
Poor ROIC 147.32%
ROE 185.25%
Asset turnover 0.01x
Debt
47 /100
Moderate Debt/Equity 0.00x
Current ratio 0.44x
Int. coverage -24.20x
Stability
13 /100
Unstable Beta 1.40x
Rev. volatility 143.96%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PROGEN.ST
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Fredrik Rickman
Employees
7
Headquarters
Nacka Strand